44 open label clinical trial
classic.clinicaltrials.gov › ct2 › showPROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER... Mar 15, 2022 · None (Open Label) Primary Purpose: Prevention: Official Title: PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS: Actual Study Start Date : July 30, 2021: Estimated Primary Completion Date : August 31, 2022: Estimated Study Completion Date : August 31, 2023 Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of ... This open-label, controlled study will evaluate the efficacy and safety of EB-101 for the treatment of large, chronic, RDEB wounds. The study intervention consists of one-time surgical application of gene-corrected keratinocyte sheets (EB-101) for the treatment of RDEB wound sites in up to approximately 10-15 participants.
Open-label extension studies: do they provide meaningful ... - PubMed Most of the value accrued in open-label extension studies...